Ignite Creation Date:
2024-05-06 @ 8:15 PM
Last Modification Date:
2024-10-26 @ 3:23 PM
Study NCT ID:
NCT06305754
Status:
RECRUITING
Last Update Posted:
2024-07-11
First Post:
2024-03-05
Brief Title:
Sacituzumab Tirumotecan MK-2870 Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor EGFR-Mutated Advanced Nonsquamous Non-small Cell Lung Cancer NSCLC and Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors MK-2870-009
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-06-11
Start Date Type:
ACTUAL
Primary Completion Date:
2028-09-12
Primary Completion Date Type:
ESTIMATED
Completion Date:
2030-06-14
Completion Date Type:
ESTIMATED
First Submit Date:
2024-03-05
First Submit QC Date:
March 5 2024
Study First Post Date:
2024-03-12
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-10-14
Last Update Post Date:
2024-07-11
Last Update Post Date Type:
ACTUAL